Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 1

Low Intensity Focused Ultrasound Modulation of Thalamic Nuclei for Central Neuropathic Pain.

NCT06978764 · tracked via the Priya Life Science Brazil tracker
Phase
Phase 1
Started
2024-11-19
Last updated
2025-05-18

Condition(s) studied

Central Neuropathic Pain

Investigational drug(s) / intervention(s)

Thalamic LIFUP

Thalamic LIFUP: Patients will receive intervention in Thalamus region by LIFUP

Study summary

LIFUP may have a modulatory effect on neuronal circuitry involved in pain, specifically when applied to the anterior thalamic nuclei, which is an important part of the pain circuit .Precise laboratory studies will reveal the indications under which LIFUP produces analgesia. The first step in evaluating LIFUP as a therapy for pain control is to determine whether LIFUP produces analgesia through suppression of the anterior thalamus. The primary objective is to evaluate the short-term analgesic effects of thalamic analgesia caused by LIFUP through:

1. Quantitative sensory testing (QST) and conditioned pain modulation testing (CPM) that allow the assessment of perceptual responses to quantifiable sensory stimuli, evaluated to characterize somatosensory function or dysfunction.
2. Short-form McGill Pain Questionnaire;
3. Brief Inventory Form, which includes pain severity index (average of questions 3-6) and pain interference with daily activities (average of questions 9A-9G, ranging from 0 to 70, where 70 indicates maximum possible pain interference);
4. Douleur Neuropathique-4 to assess neuropathic pain, being positive for scores ≥4;
5. Neuropathic Pain Symptom Inventory (NPSI), which provides characterization of neuropathic pain symptoms in 5 domains (superficial and deep) spontaneous pain, paroxysmal pain, evoked pain and paresthesia.

In association, analysis of its responses with others qualitative scales will be made described above:

1. Hamilton D + A
2. Medication use (Brief Pain Inventory)
3. Interference with daily activities (Brief Pain Inventory, quantified by Medication Quantification Scale)
4. Cognition - Montreal Cognitive Assessment (Mo CA)5 Adverse events
5. Blinding assessment
6. Variation in Global Impression of Change (CGI)

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female more than 18 years old; * Persistent presence of pain from braquial plexopathy injury for more than 3 months with an average of pain scoring of four or more points in numeric verbal scale (refractory to treatments). Exclusion Criteria: * history of uncontrolled epilepsy * history of depression * surgery or hospitalizations in the last 6 months * presence of metal brain implants * history of alcohol or drug addiction * pregnancy * history of loss of consciousness lasting more than 15 minutes

Primary outcome measure(s)

  • Pain assessments — Before and immediately after intervention. Also 4 hours, 24 hours, 10 days and 28 days after intervention.
    Pain scores in Visual Analog Scale has a numeric scoring that measures the intensity of pain from a scale of 1 to 10. The higher numeric scoring of the scale suggests severity and worse pain sensations. The scale will be analyzed before and after application of low-intensity pulsed ultrasound on the anterior thalamus.

Trial sites (1)

FacilityCityRegionStatus
Neurology Department HCFMUSP São Paulo São Paulo
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06978764 on ClinicalTrials.gov ↗ ← All trials in Brazil